MX388831B - Metodos y composiciones para esteres anticolinergicos suaves. - Google Patents

Metodos y composiciones para esteres anticolinergicos suaves.

Info

Publication number
MX388831B
MX388831B MX2018003002A MX2018003002A MX388831B MX 388831 B MX388831 B MX 388831B MX 2018003002 A MX2018003002 A MX 2018003002A MX 2018003002 A MX2018003002 A MX 2018003002A MX 388831 B MX388831 B MX 388831B
Authority
MX
Mexico
Prior art keywords
compositions
methods
sialorrhea
intra
anticholinergic esters
Prior art date
Application number
MX2018003002A
Other languages
English (en)
Spanish (es)
Other versions
MX2018003002A (es
Inventor
Nicholas S Bodor
Original Assignee
Bodor Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bodor Laboratories Inc filed Critical Bodor Laboratories Inc
Publication of MX2018003002A publication Critical patent/MX2018003002A/es
Publication of MX388831B publication Critical patent/MX388831B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2018003002A 2015-09-11 2016-09-06 Metodos y composiciones para esteres anticolinergicos suaves. MX388831B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562217362P 2015-09-11 2015-09-11
PCT/US2016/050385 WO2017044412A1 (en) 2015-09-11 2016-09-06 Methods and compositions for soft anticholinergic esters

Publications (2)

Publication Number Publication Date
MX2018003002A MX2018003002A (es) 2018-08-01
MX388831B true MX388831B (es) 2025-03-20

Family

ID=58239861

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003002A MX388831B (es) 2015-09-11 2016-09-06 Metodos y composiciones para esteres anticolinergicos suaves.

Country Status (12)

Country Link
US (4) US11534422B2 (enExample)
EP (1) EP3347007B1 (enExample)
JP (4) JP7270958B2 (enExample)
KR (1) KR102889909B1 (enExample)
CN (4) CN118045082A (enExample)
AU (2) AU2016318595B2 (enExample)
ES (1) ES2942361T3 (enExample)
IL (1) IL257970B (enExample)
MX (1) MX388831B (enExample)
MY (1) MY197265A (enExample)
WO (1) WO2017044412A1 (enExample)
ZA (1) ZA201801685B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109044965A (zh) * 2018-10-17 2018-12-21 广州大光制药有限公司 格隆溴铵的眼用药物组合物及医药用途
US20230149349A1 (en) * 2020-03-03 2023-05-18 Kaken Pharmaceutical Co., Ltd. Medicament containing sofpironium bromide
CN118119392A (zh) 2021-11-01 2024-05-31 犹他大学研究基金会 用于治疗流涎的组合物和方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2879100A (en) * 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
WO2001008681A1 (en) 1999-08-02 2001-02-08 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
US9198897B2 (en) * 2005-01-19 2015-12-01 Neurohealing Pharmaceuticals, Inc. Methods and compositions for decreasing saliva production
ATE529399T1 (de) 2005-11-10 2011-11-15 Nicholas S Bodor Sanfte anticholinerge ester
EP1957451B1 (en) 2005-11-10 2011-10-19 Nicholas S. Bodor Soft anticholinergic zwitterions
US8071693B2 (en) 2006-06-22 2011-12-06 Sabic Innovative Plastics Ip B.V. Polysiloxane/polyimide copolymers and blends thereof
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
JP2010530902A (ja) 2007-06-22 2010-09-16 サイエル ファーマ,インコーポレイティド 流涎症治療のためのグリコピロレートを含む経皮送達システム
US8628729B2 (en) 2008-03-27 2014-01-14 President And Fellows Of Harvard College Three-dimensional microfluidic devices
JP6223543B2 (ja) * 2013-03-15 2017-11-01 ボドール ラボラトリーズ, インコーポレイテッド 多汗症の処置のための抗コリン作用性グリコピロレートエステル

Also Published As

Publication number Publication date
US12458625B2 (en) 2025-11-04
MY197265A (en) 2023-06-08
WO2017044412A1 (en) 2017-03-16
HK1255558A1 (en) 2019-08-23
ES2942361T3 (es) 2023-05-31
JP2022132446A (ja) 2022-09-08
JP2018526420A (ja) 2018-09-13
KR20180061220A (ko) 2018-06-07
JP2021001238A (ja) 2021-01-07
CN118045082A (zh) 2024-05-17
AU2021204306A1 (en) 2021-07-22
US20240261262A1 (en) 2024-08-08
CN108348502A (zh) 2018-07-31
JP2023164671A (ja) 2023-11-10
EP3347007B1 (en) 2023-03-29
US11951093B2 (en) 2024-04-09
JP7270958B2 (ja) 2023-05-11
CN118021797A (zh) 2024-05-14
IL257970A (en) 2018-05-31
AU2016318595B2 (en) 2021-07-08
IL257970B (en) 2021-04-29
CN118021770A (zh) 2024-05-14
KR102889909B1 (ko) 2025-11-24
US20180250265A1 (en) 2018-09-06
JP7723417B2 (ja) 2025-08-14
US20220401410A1 (en) 2022-12-22
ZA201801685B (en) 2023-12-20
EP3347007A1 (en) 2018-07-18
EP3347007A4 (en) 2019-05-08
US11534422B2 (en) 2022-12-27
AU2021204306B2 (en) 2023-11-09
US20260108491A1 (en) 2026-04-23
AU2016318595A1 (en) 2018-04-26
CA2998357A1 (en) 2017-03-16
MX2018003002A (es) 2018-08-01

Similar Documents

Publication Publication Date Title
PH12016501732B1 (en) Formulation for soft anticholinergic analogs
JOP20200011B1 (ar) مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
MX2018000918A (es) Formulacion para analogos anticolinergicos blandos.
EP3273944A4 (en) COMPOSITIONS AND METHODS OF DISTRIBUTING BIOMACROMOLOLE-ACIDS
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
PH12019500142A1 (en) Formulation for soft anticholinergic analogs
MX391489B (es) Inhibidores heterociclicos de mct4.
MX2017017119A (es) Formulacion de alta concentracion.
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
NZ702087A (en) Pharmaceutical compositions and treatment of mastitis
UA120999C2 (uk) Естери оксаборолу та їх використання
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
PH12016500910A1 (en) Long-acting ketoprofen compositions
ZA201801685B (en) Methods and compositions for soft anticholinergic esters
BR112015016391A2 (pt) carboxamidas i baseadas em pirazolil como inibidoras do canal crac
EA201692493A1 (ru) Противомикробные фармацевтические композиции со способностями ингибирования множественной лекарственной устойчивости
BR112015016394A2 (pt) carboxamidas ii baseadas em pirazolil como inibidoras do canal crac
MX373177B (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
EA201792685A1 (ru) Фармацевтическая композиция для лечения воспалительных изменений прямой кишки
HUE043237T2 (hu) Propoliszt és karnozinsavat tartalmazó szinergikus készítmény kandidiázis megelõzésében és kezelésében történõ alkalmazásra
AR099681A1 (es) Composiciones de grapiprant y métodos para su utilización